Ethics code: Review article

XML Print


Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (1 Views)
Human papillomavirus (HPV) infection is highly prevalent worldwide and causes a substantial burden of anogenital and oropharyngeal disease. Although most infections resolve spontaneously, persistent infection with oncogenic HPV types can cause cervical and other HPV-associated cancers. The E6 and E7 oncoproteins sustain the malignant phenotype by disrupting p53- and retinoblastoma-associated tumor-suppressive pathways, respectively. Prophylactic L1 virus-like particle (VLP) vaccines prevent new infections but do not eliminate established HPV infections or HPV-associated lesions. Therapeutic DNA vaccines encoding E6 and E7 are therefore under investigation to induce antigen-specific cellular immunity against infected and transformed cells. These plasmid-based vaccines offer manufacturing flexibility, relative stability, and opportunities for repeated administration, but their clinical performance can be limited by inefficient delivery, antigen presentation, and immunosuppressive tumor microenvironments. This narrative review examines HPV biology and host immunity, the design and mechanisms of E6/E7 DNA vaccines, and approaches to improve their immunogenicity, including antigen engineering, codon optimization, dendritic cell targeting, electroporation, and combination immunotherapy. We critically summarize preclinical and clinical findings, distinguish DNA vaccines from other therapeutic platforms, and discuss the remaining challenges to clinical translation. Although several DNA-vaccine candidates have shown immunogenicity and activity against cervical precancer, convincing efficacy in advanced malignancies and broad clinical implementation remain unestablished.
     
Type of Study: Review article | Subject: Immune responses, deficiencies and vaccine candidates
Received: 2026/11/16 | Accepted: 2026/09/10

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.